In this issue:
Treatment and outcomes in highrisk, newly diagnosed del(17p) MM
Twice-weekly ixazomib + lenalidomide/dexamethasone for new MM
Treatment intensification with SCT + lenalidomide in new MM in CR
Risk factors for blood stream infections in MM
Bortezomib maintenance in SCT-ineligible plateaued MM after bortezomib induction
Low dose lenalidomide + dexamethasone in newly diagnosed POEMS syndrome
Large focal lesions is strongly prognostic in MM
Modified lenalidomide, bortezomib and dexamethasone regimen in transplant-ineligible MM
CAR-BCMA T-cells lead to remission in poor-prognosis relapsed MM
Loss of heterozygosity indicates homologous repair deficiency in MM
Please login below to download this issue (PDF)